David A Scheinberg

This inventor holds 51 USPTO granted patents and 34 published patent applications, plus 6 CIPO patents and 11 EPO patents, primarily in Cancer Immunotherapy. Top assignees: Memorial Sloan Kettering Cancer Center, Sloan-Kettering Institute for Cancer Research, Eureka Therapeutics, Inc.. Active years: 1998-2026.

USPTO Granted Patents = 51 (Patent Applications = 34)

% Patents Active = 74.5

CIPO Patents = 6 (Patent Applications = 15)

EPO Patents = 11 (Patent Applications = 33)

Average Co-Inventor Count = 2.9

ph-index = 13

Forward Citations = 1,112(Granted Patents)

Company Filing History:

25 out of 615

Memorial Sloan Kettering Cancer Center

patents

21 out of 517

Sloan-Kettering Institute for Cancer Research

patents

8 out of 52

Eureka Therapeutics, Inc.

patents

4. 2 out of 29

Protein Design Labs, Inc.

Sloan-Kettering Cancer Center

patents

7. 4 out of 834,307

Other

patents

where one patent can have more than one assignee

Years Active: 1998-2026

Loading Chart...

Areas of Expertise:

Adoptive Cell Therapy

WT1 Peptides

Cancer Treatment

Nanotube Constructs

T Cell Receptor Antibodies

Immunogenic Peptides

Therapeutic Agents

Alpha Emitting Constructs

Targeted Delivery

Inflammasome RNA Interference

Monoclonal Antibodies

Prostate Specific Antigens

51 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12528849 - WT1 HLA CLASS II-BINDING PEPTIDES AND COMPOSITIONS AND METHODS COMPRISING SAME (2026-01-20),

2. 12496310 - COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY (2025-12-16),

3. 12343407 - Inflammasome-targeted RNA interference approach to treating kidney injury and disease (2025-07-01),

4. 12241097 - Compositions and methods for adoptive cell therapy for cancer (2025-03-04),

5. 12178830 - Compositions and methods for adoptive cell therapy for cancer (2024-12-31),

6. 11859015 - Immunogenic WT-1 peptides and methods of use thereof (2024-01-02),

7. 11660357 - One-step labeling of antibodies to high specific activity with actinium-225 (2023-05-30),

8. 11564988 - Single wall nanotube constructs and uses thereof (2023-01-31),

9. 11548924 - WT1 HLA class II-binding peptides and compositions and methods comprising same (2023-01-10),

10. 11505599 - T cell receptor-like antibodies specific for Foxp3-derived peptides (2022-11-22),

11. 11414457 - Immunogenic WT-1 peptides and methods of use thereof (2022-08-16),

12. 11384144 - T cell receptor-like antibodies specific for a PRAME peptide (2022-07-12),

13. 11242405 - Monoclonal antigen-binding proteins to intracellular oncogene products (2022-02-08),

14. 11185501 - Method and composition for targeted delivery of therapeutic agents (2021-11-30),

15. 11033613 - Methods and compositions for treating cancer (2021-06-15),

Sure, I would be delighted to assist you with that. Here is the article about inventor David A Scheinberg:

Title: David A Scheinberg - A Trailblazer in Innovations and Patents

Introduction:

David A Scheinberg, a distinguished inventor based in New York, NY (US), is renowned for his unwavering dedication to innovation and scientific advancement. With an impressive portfolio of 46 patents, he is recognized as a trailblazer in the world of inventions and patents.

Latest Patents:

1. Immunogenic WT-1 peptides and methods of use thereof: This groundbreaking invention offers peptides, immunogenic compositions, and vaccines designed to treat WT1-expressing cancers. The heteroclitic peptides derived from the WT-1 protein pave the way for novel treatment approaches in cancer immunotherapy.

2. One-step labeling of antibodies to high specific activity with actinium-225: Scheinberg's invention introduces a revolutionary one-step method for chelating actinium-225 to bio-molecules like antibodies. This method enhances the radiochemical yield of actinium-225 complexes and opens new avenues for treating neoplastic diseases with high specific activity actinium-225 complexes.

Career Highlights:

David A Scheinberg has made significant contributions to the field of cancer research during his tenure at the Sloan-Kettering Institute for Cancer Research and Memorial Sloan Kettering Cancer Center. His innovative work has paved the way for groundbreaking advancements in cancer treatment and immunotherapy.

Collaborations:

Throughout his career, Scheinberg has collaborated closely with esteemed colleagues such as Michael R McDevitt and Tao Dao. These collaborations have been instrumental in driving forward cutting-edge research and development initiatives in the field of cancer therapeutics.

Conclusion:

In conclusion, David A Scheinberg's relentless pursuit of scientific excellence and his groundbreaking inventions underscore his status as a true trailblazer in the realm of innovations and patents. His innovative contributions have significantly impacted the field of cancer research, offering new hope and possibilities for patients worldwide.